An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial
Khanna D et al. J Rheumatol 216; 43: 1672–1679. doi: 10.3899/jrheum.151322
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.